Guerbet

GBTFR0000032526

Guerbet is a France-based manufacturer of contrast agents used in medical imaging. The company was founded in 1926 by André Guerbet, the son of Marcel Guerbet who in 1901 discovered Lipiodol – the first iodinated X-ray contrast agent.

Filings

14 filings

All Inside information23 Voting rights and capital18 Earnings release14 Share buyback7 Universal registration document5 Corporate governance4 Half-year financial report1 Threshold crossing1

23/07/2026
Guerbet : H1 2026 revenue.
Earnings releaseFR
23/04/2026
Q1 2026 revenue
Earnings releaseFR
11/03/2026
GUERBET : 2025 full-year results.
Earnings releaseFR
23/10/2025
Guerbet : Revenue at September 30, 2025. Return to growth in Q3 2025. Confirmation of all financial targets for 2025.
Earnings releaseFR
24/09/2025
Guerbet : H1 2025 results : H1 revenue: €387.8 million, down 5.4% at CER and on a like-for-like basis, mainly due to the decline in activity in France
Earnings releaseFR
24/07/2025
Guerbet : H1 2025 revenue
Earnings releaseFR
26/03/2025
GUERBET : 2024 full-year results.
Earnings releaseFR

About

ISIN: FR0000032526
Ticker: GBT
LEI: 969500WV1U1WQ059L135
Founded: 1926
Country of registration: FR
Last filing: 23/07/2026, 17:45

Wikipedia

Description from Wikidata, CC0 licence.

Filing history

Filings per month

Sept 23May 24Jan 25Sept 25Aug 26

Document types

Across the whole archive